Thermo Fisher Scientific LCK Polyclonal Antibody, MaxPab

Applications

• Western Blot (WB): 1:500–1:1,000
• in situ PLA (PLA): 1:1200

Product Specifications

Product Specific Information

Sequence of this protein is as follows:
MGCGCSSHPE DDWMENIDVC ENCHYPIVPL DGKGTLLIRN GSEVRDPLVT YEGSNPPASP LQDNLVIALH SYEPSHDGDL GFEKGEQLRI LEQSGEWWKA QSLTTGQEGF IPFNFVAKAN SLEPEPWFFK NLSRKDAERQ LLAPGNTHGS FLIRESESTA GSFSLSVRDF DQNQGEVVKH YKIRNLDNGG FYISPRITFP GLHELVRHYT NASDGLCTRL SRPCQTQKPQ KPWWEDEWEV PRETLKLVER LGAGQFGEVW MGYYNGHTKV AVKSLKQGSM SPDAFLAEAN LMKQLQHQRL VRLYAVVTQE PIYIITEYME NDTLLDSQLE EKGLGASPWG NLGQQLLLLP TGSLVDFLKT PSGIKLTINK LLDMAAQIAE GMAFIEERNY IHRDLRAANI LVSDTLSCKI ADFGLARLIE DNEYTAREGA KFPIKWTAPE AINYGTFTIK SDVWSFGILL TEIVTHGRIP YPGMTNPEVI QNLERGYRMV RPDNCPEELY QLMRLCWKER PEDRPTFDYL RSVLEDFFTA TEGQYQPQP

Target Information

LCK is a member of the Src-family tyrosine kinase, essential for signaling through the T-cell receptor (TCR) complex. Upon TCR triggering, LCK phosphorylates ITAM motifs in zeta subunits, creating binding sites for the SH2 domains of ZAP70, which LCK also phosphorylates and activates. Activated ZAP70 generates signaling platforms through adaptor LAT phosphorylation. Most LCK localizes to the plasma membrane, with some associated with the Golgi apparatus, potentially contributing to Raf activation under weak TCR stimulation.
LCK contains N-terminal sites for myristylation and palmitylation, a PTK domain, and SH2/SH3 domains mediating interactions with phosphotyrosine-containing and proline-rich motifs. It also regulates apoptosis induced by various stimuli (excluding death receptors).
Diseases associated with LCK include Immunodeficiency 22 and CD45 deficiency. Alternatively spliced variants encoding different isoforms have been identified.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.